BioNexus Gene Lab Corp. Files 8-K for Material Agreement
Ticker: BGLC · Form: 8-K · Filed: Sep 25, 2024 · CIK: 1737523
| Field | Detail |
|---|---|
| Company | Bionexus Gene Lab CORP (BGLC) |
| Form Type | 8-K |
| Filed Date | Sep 25, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-k
TL;DR
BioNexus Gene Lab Corp. signed a big deal on 9/23, filed 8-K on 9/25.
AI Summary
BioNexus Gene Lab Corp. announced on September 25, 2024, that it entered into a material definitive agreement on September 23, 2024. The company, incorporated in Wyoming, filed an 8-K report detailing this event. The filing does not specify the nature of the agreement or any associated dollar amounts.
Why It Matters
This filing indicates a significant development for BioNexus Gene Lab Corp., potentially impacting its business operations and future strategy.
Risk Assessment
Risk Level: medium — The filing is a standard 8-K for a material agreement, but the lack of specific details about the agreement introduces uncertainty.
Key Players & Entities
- BioNexus Gene Lab Corp. (company) — Filer of the 8-K report
- September 25, 2024 (date) — Date of the 8-K filing
- September 23, 2024 (date) — Date of the material definitive agreement
- Wyoming (jurisdiction) — State of incorporation for BioNexus Gene Lab Corp.
FAQ
What is the nature of the material definitive agreement entered into by BioNexus Gene Lab Corp.?
The filing does not specify the nature of the material definitive agreement.
What is the effective date of the material definitive agreement?
The material definitive agreement was entered into on September 23, 2024.
When did BioNexus Gene Lab Corp. file the 8-K report?
BioNexus Gene Lab Corp. filed the 8-K report on September 25, 2024.
In which state is BioNexus Gene Lab Corp. incorporated?
BioNexus Gene Lab Corp. is incorporated in Wyoming.
Are there any specific financial terms or dollar amounts mentioned in relation to the agreement?
No specific financial terms or dollar amounts are mentioned in this filing regarding the agreement.
Filing Stats: 714 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2024-09-25 11:30:33
Filing Documents
- bglc_8k.htm (8-K) — 29KB
- bglc_ex101.htm (EX-10.1) — 18KB
- bglc_ex991.htm (EX-99.1) — 11KB
- 0001477932-24-005924.txt ( ) — 189KB
- bglc-20240923.xsd (EX-101.SCH) — 6KB
- bglc-20240923_lab.xml (EX-101.LAB) — 14KB
- bglc-20240923_cal.xml (EX-101.CAL) — 1KB
- bglc-20240923_pre.xml (EX-101.PRE) — 9KB
- bglc-20240923_def.xml (EX-101.DEF) — 2KB
- bglc_8k_htm.xml (XML) — 4KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On September 23, 2024, MRNA Scientific Sdn. Bhd. ("MRNA"), a wholly-owned subsidiary of BioNexus Gene Lab Corp. (the "Company"), entered into a teaming agreement (the "Agreement") with Protech Builders Sdn. Bhd. ("Protech"), a Malaysian mechanical and electrical engineering firm. Pursuant to the Agreement, the Company and Protech have agreed to collaborate on the development, marketing, and operation of biogas plants across Malaysia. The Agreement establishes a three-year term during which the parties will jointly identify and pursue biogas project opportunities, particularly focusing on converting plantation wastewater into renewable energy. Key terms of the Agreement include: Initial Contributions: MRNA and Protech will each contribute up to RM500,000 towards joint marketing and project development activities, including feasibility studies and preliminary project costs. Project Financing: Any biogas projects realized under this collaboration will be financed jointly by the parties, with specific financial contributions to be determined on a project-by-project basis through further negotiation. Management and Governance: The Agreement establishes a Joint Steering Committee (JSC), comprised of representatives from both MRNA and Protech, to oversee the progress of joint activities and make strategic decisions. The Agreement is subject to customary terms and conditions, including provisions for confidentiality, dispute resolution, and termination. The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, copies of which are filed as Exhibit 10.1 to this current report on Form 8-K.
01 Other Events
Item 8.01 Other Events. On September 25, 2024, the Company issued a press release announcing the entry into biogas sector in Malaysia via the Agreement with Protech. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
01 Financial Statement and Exhibits
Item 9.01 Financial Statement and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 The Teaming Agreement between MRNA Scientific Sdn. Bhd. and Protech Builders Sdn. Bhd. for Biogas Plant Development, dated September 23, 2024. 99.1 Press release announcing the entry into biogas sector in Malaysia via the Agreement with Protech, issued on September 25, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioNexus Gene Lab Corp. /s/ Su-Leng Tan Lee By: Su-Leng Tan Lee Chief Executive Officer Date: September 25, 2024 3